Osteopenia News and Research

RSS

Osteopenia is a condition where bone mineral density is lower than normal. It is considered by many doctors to be a precursor to osteoporosis. However, not every person diagnosed with osteopenia will develop osteoporosis. More specifically, osteopenia is defined as a bone mineral density T-score between -1.0 and -2.5.

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.

2 Jul 2010

Use of bisphosphonates associated with risk of developing BON after dental surgery: Study

People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning of the bones) may be unfamiliar with the drug and possible adverse side effects on oral health, according to a study in the May issue of The Journal of the American Dental Association.

27 May 2010

$Seniors who consume high dietary protein are less likely to suffer hip fractures$

Seniors who consume high dietary protein are less likely to suffer hip fractures

Seniors who consume a higher level of dietary protein are less likely to suffer hip fractures than seniors whose daily dietary protein intake is less, according to a new study by the Institute for Aging Research of Hebrew SeniorLife in Boston, an affiliate of Harvard Medical School.

5 May 2010

Gilead Sciences doses first patient in Quad Phase III clinical program

Gilead Sciences, Inc. today announced that it has dosed the first patient in the Phase III clinical program evaluating its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat (formerly GS 9350), emtricitabine and tenofovir disoproxil fumarate.

13 Apr 2010

$Osteoporosis drugs falsely implicated in rare thigh bone fractures, say new reports$

Osteoporosis drugs falsely implicated in rare thigh bone fractures, say new reports

Osteoporosis is a disease of the bones usually affecting elderly women and causes the bones to become brittle and easily breakable. Since last two years some alarming reports of women on drugs for therapy of this disease have come to notice. These reports show that these drugs intended for therapy may result in rare and serious fractures of their thigh bones where the bones break clean or may splinter. Often these fractures were not associated with any fall or impact. Moreover some of the sufferers are middle aged women in their 50’s who do not have full blown osteoporosis, a condition known as pre-osteoporosis or osteopenia.

25 Mar 2010

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

18 Feb 2010

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose “Quad” regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.

7 Jan 2010

NAMS recommends women to discuss osteoporosis with their OB/GYNs

According to a new survey distributed by The North American Menopause Society (NAMS), while 98 percent of women who participated consider bone strength to be an important health concern, nearly half (45 percent) of these women reported that osteoporosis was not addressed during their last routine OB/GYN visit, and more than a quarter (26.4 percent) of women surveyed have never discussed osteoporosis with their OB/GYN.

14 Dec 2009

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed clinicians say they will use Amgen/GlaxoSmithKline's Prolia as either a second- or third-line therapy for osteoporosis if the drug receives regulatory approval for the indication.

4 Dec 2009

Spine Care Institute established by Hospital for Special Surgery

Hospital for Special Surgery today announced the establishment of one of the most comprehensive centers of excellence in the country for the treatment of all nonoperative and operative spine disorders.

16 Nov 2009

Effects of vitamin D deficiency amplified by lower levels of sex hormone estrogen

Researchers at Johns Hopkins are reporting what is believed to be the first conclusive evidence in men that the long-term ill effects of vitamin D deficiency are amplified by lower levels of the key sex hormone estrogen, but not testosterone.

16 Nov 2009

U.S. Patent and Trademark Office awards new patent for Ryogen

Ryogen LLC, a genomic start-up company, has been awarded a new patent titled “Isolated Genomic Polynucleotide Fragments from Chromosome 7”.

12 Nov 2009

New medical guidelines for accurate diagnosis and ethical treatment of growth hormone deficiency

Today the American Association of Clinical Endocrinologists (AACE) released new medical guidelines for the accurate diagnosis and effective ethical treatment of growth hormone deficiency in affected patients.

4 Nov 2009

Gilead Sciences to present Viread Phase III clinical trial data

Gilead Sciences, Inc. today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.

2 Nov 2009

Osteologix to continue clinical development of NB S101 osteoporosis drug

Osteologix, Inc., a bio-pharmaceutical company announced today that the company will continue the clinical development for its osteoporosis drug, NB S101 (strontium malonate), in the United States and the rest of the world markets. Additionally, the company wants to recognize World Osteoporosis Day’s significance and make more people aware of its research dedicated to improving the lives of people with osteoporosis.

21 Oct 2009

Metabolic bone disease in cirrhosis patients

Long-standing liver disease has long been recognized to result in fragile bones with increased risk of fractures. In various international studies, the overall incidence has varied from 11% to 48%, with a fracture rate of 3%-44%.

10 Aug 2009

FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

Reclast (zoledronic acid) Injection has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose. Reclast is already approved as a once-yearly infusion for the treatment of postmenopausal osteoporosis.

1 Jun 2009

$Older women underestimate risk of bone fracture$

Older women underestimate risk of bone fracture

Most women who are likely to have a bone fracture do not think they are at greater risk, said a leading Italian rheumatologist at a European conference. This could help to explain why many women do not adhere to preventive treatment.

24 May 2009

FABLYN approved in Europe as osteoporosis treatment

Ligand Pharmaceuticals Incorporated has announced that its partner, Pfizer, Inc. has received approval from the European Commission (EC) for FABLYN (lasofoxifene) Tablets, a selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in post-menopausal women at increased risk of fracture.

24 Mar 2009

Osteoporosis linked to vertigo

People who have osteoporosis are more likely to also have vertigo, according to a study published in the March 24, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology.

23 Mar 2009